Loading patent…
AssigneesYunnan Precious Metals Laboratory Co., Ltd, Kunming Medical University
InventorsWeiping Liu, Chen Qing, Anli Gao, Peng Zhou, Jing Jiang, Hongyu Zhou, Juan Yu, Lingling Zhang
Estimating the term…
Provided is an oral Pt(IV) anticancer prodrug containing a 3-bromopyruvate as an axial ligand, with a molecular formula of cis,trans,cis-[Pt(1R,2R-diaminocyclohexane)(OH)(3-bromopyruvate)(C2O4)]. It is a prodrug of oxaliplatin and 3-bromopyruvic acid is a small molecular glycolysis inhibitor. The prodrug is able to simultaneously act on DNA replication and glycolytic pathways of cancer cells, giving full play to the advantage of double-acting targets. The oral Pt(IV) anticancer prodrug is synthesized by using oxaliplatin as a starting material, performing axial oxidation with H2O2 and neutralizing the oxidized product with 3-bromopyruvic acid.
An oral Pt(IV) anticancer prodrug containing 3-bromopyruvate, a small molecular glycolysis inhibitor, as an axial ligand, with a molecular formula of cis,trans,cis-[Pt(1R,2R-diaminocyclohexane)(OH)(3-bromopyruvate)(C2O4)], wherein the oral Pt(IV) anticancer prodrug has a chemical structure as follows:
Dependencies are inferred from the claim text.